CoVPN Trial: Novavax’s Traditional COVID-19 Vaccine Correlates to Strong Antibody Response, Protection Against SARS-CoV-2

A new analysis of the Novavax PREVENT-19 clinical trial concluded that this recombinant protein vaccine produced an antibody response comparable to mRNA vaccines and, if authorized, could help bolster global vaccine supplies. This is the first study to directly support antibody correlates of protection for a recombinant protein COVID-19 vaccine.